Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 370 | 53 | 314 |
| Samples | 192 | 39 | 151 |
| Peptides | 140 | 26 | 118 |
Function
ERVFRD-1 · Endogenous retrovirus group FRD member 1, envelope
Many different human endogenous retrovirus (HERV) families are expressed in normal placental tissue at high levels, suggesting that HERVs are functionally important in reproduction. This gene is part of a human endogenous retrovirus provirus on chromosome 6 that has inactivating mutations in the gag and pol genes. This gene is the envelope glycoprotein gene which appears to have been selectively preserved. The gene's protein product plays a major role in placental development and trophoblast fusion. The protein has the characteristics of a typical retroviral envelope protein, including a cleavage site that separates the surface (SU) and transmembrane (TM) proteins which form a heterodimer. [provided by RefSeq, Jun 2012].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 140 amino-acid changes on canonical ENST00000472091 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ERVFRD-1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ERVFRD-1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 6/42 14% | 13/612 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Melanoma | 6/210 3% | 17/1899 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 12/1390 1% |
| Colorectal Carcinoma | 7/143 5% | 22/3239 1% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 3/810 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Gastric Carcinoma | 0/74 0% | 14/1809 1% |
| Other Solid Cancers | 1/94 1% | 10/1515 1% |
| Non-Cancerous | 0/104 0% | 6/830 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Ovarian Carcinoma | 0/109 0% | 4/998 0% |
| Hepatocellular Carcinoma | 0/46 0% | 8/2210 0% |
| Biliary Tract Carcinoma | 1/54 2% | 2/950 0% |
| Head and Neck Carcinoma | 1/85 1% | 4/1574 0% |
| Kidney Carcinoma | 0/85 0% | 5/1862 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Bladder Carcinoma | 1/58 2% | 1/956 0% |
| Breast Carcinoma | 0/144 0% | 5/3264 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 4/2550 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 2/2534 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
Mutation Distribution
Where ERVFRD-1 is mutated · all tissues, split by cell line vs tissue
How many mutations in ERVFRD-1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 46 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 370 mutations in ERVFRD-1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|